Expanding cell analysis portfolio, Agilent acquires Luxcel Biosciences

Jan. 10, 2018

The acquisition expands Agilent's portfolio with the addition of assay kits that are compatible with industry-standard plate readers.

Agilent Technologies (Santa Clara, CA) has acquired Luxcel Biosciences (Cork, Ireland), which develops real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands Agilent's cell analysis portfolio with the addition of assay kits that are compatible with industry-standard plate readers.

Luxcel is developing a portfolio of in vitro cell-based assay kits and solutions targeting cell metabolism, drug safety and toxicity, as well as hypoxia and oxidative stress for a variety of life science customers from research institutions to pharmaceutical companies. Scientists use this technology to understand the roll of cell metabolism across a variety of important research areas, including cancer, metabolic disorders, cardiovascular disease, immunology, and infectious disease.

Founded in 2002 by Richard Fernandes and Dmitri Papkovsky as a spinout company from University College Cork and a member of the High Potential Start Up program at Enterprise Ireland, Luxcel has 12 employees and is headquartered in Cork. The Luxcel team will remain in Cork and form a dedicated sensor chemistries and bioassay solutions group within Agilent's Cell Analysis Division. Financial terms of the deal are not being disclosed.

For more information, please visit www.agilent.com and www.luxcel.com.